Novo Nordisk stock news
On September 7, 2026, Novo Nordisk announced positive results from the STEP Young Phase 3 clinical trial, demonstrating that 40.4% of children aged 6 to under 12 living with obesity achieved a body mass index (BMI) below the obesity threshold after 68 weeks of treatment with once--weekly semaglutide (2.4 mg). The trial met its primary endpoint of superior BMI reduction compared to placebo, with a safety and tolerability profile consistent with previous studies in adults and adolescents. This clinical milestone supports the potential regulatory expansion of the Wegovy franchise into the pediatric market, addressing a significant unmet medical need in global healthcare.